Posted by Michael Wonder on 15 Nov 2021
Supporting Australians with rare stomach and bowel cancer
15 November 2021 - The Morrison Government will list Qinlock (ripretinib) on the PBS for the treatment of advanced gastro-intestinal stromal tumour.
Without PBS subsidy, around 50 patients each year might pay more than $179,900 per course of treatment. Instead, they will pay a maximum of $41.30 per script or $6.60 with a concession card.
